$ANIK News
Last published 5d ago
- 5d agoANIKAnika Therapeutics, Inc. - PRESS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 5d agoANIKAnika Reports Third Quarter 2026 Financial ResultsGlobeNewswireRevenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff
- 5d agoANIKAnika Reports Third Quarter 2026 Financial ResultsGlobeNewswireRevenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue Secured New 10-Year...
- 2w agoANIKAnika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026GlobeNewswireBEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter
- 3mo agoABBVJNJINMDANIK+1Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next OneGlobeNewswireNEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator
- 3mo agoANIKAnika Reports Second Quarter 2026 Financial ResultsGlobeNewswireCommercial Channel Revenue Increased 17% to a Record $13.9 Million Delivered $3.3 Million of Net Income, 65% Gross Margin, and $7.1 Million of Adjusted EBITDA, Highest Since 2020 Raising Full-Year 2026 Financial
- 3mo agoANIKAnika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026GlobeNewswireBEDFORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter
- 5mo agoANIKAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention
- 6mo agoACRXANIKAXGNBEAT+6TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesGlobeNewswireMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a
- 6mo agoANIKAnika Reports First Quarter 2026 Financial ResultsGlobeNewswireGrew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execution Operational
- 6mo agoANIKXLOXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of DirectorsGlobeNewswireWALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with
- 7mo agoANIKAnika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026GlobeNewswireBEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter
- 7mo agoANIKAVNTCOOMASI+3Telix Strengthens Board with Additional Director AppointmentsGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments,
- 7mo agoANIKAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention
- 8mo agoANIKAnika Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireMet 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating
- 8mo agoANIKAnika To Present at the Canaccord Genuity 2026 Musculoskeletal ConferenceGlobeNewswireBEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of
- 9mo agoANIKAnika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026GlobeNewswireBEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and
- 9mo agoANIKLumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of DirectorsPR NewswireLumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of...
- 10mo agoANIKAnika Therapeutics Announces Leadership TransitionGlobeNewswireStephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass.,
- 10mo agoANIKANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLPBusiness WireThe law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ:ANIK) investors concerning the Company's and/or members of its senior
- 11mo agoANIKAnika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIKGlobeNewswireNEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ:ANIK). The investigation concerns
- 1y agoANIKAnika Reports Third Quarter 2025 Financial ResultsGlobeNewswireCommercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed
- 1y agoANIKAnika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III StudyGlobeNewswireBEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module of its
- 1y agoANIKAnika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025GlobeNewswireBEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025
- 1y agoANIKAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention
- 1y agoANIKKirby McInerney LLP Announces Investigation Against Anika Therapeutics, Inc. (ANIK) on Behalf of InvestorsGlobeNewswireNEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ:ANIK). The investigation concerns
- 1y agoANIKAnika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoANIKAnika Reports Second Quarter 2025 Financial ResultsGlobeNewswireRegenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than
- 1y agoANIKAnika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program UpdateGlobeNewswireHyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed
- 1y agoANIKAnika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025GlobeNewswireBEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter
- 1y agoANIKAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention
- 1y agoANIKAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention
- 1y agoANIKAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention
- 1y agoANIKAnika Reports First Quarter 2025 Financial ResultsGlobeNewswireFirst Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved
- 1y agoANIKAnika to Participate in the Sidoti Virtual Investor ConferenceGlobeNewswireBEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention
- 1y agoANIKAnika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025GlobeNewswireBEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter
- 1y agoANIKAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the Osteoarthritis ("OA") Pain Management and Regenerative Solutions space focused on early intervention
- 1y agoANIKAnika Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireFull Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial
- 1y agoANIKAnika Completes Divestiture of Parcus MedicalGlobeNewswireBEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space focused on early intervention
- 1y agoANIKAnika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025GlobeNewswireBEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and
- 1y agoANIKAnika To Present at the Canaccord Genuity 2025 Musculoskeletal ConferenceGlobeNewswireBEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and
- 1y agoANIKAnika To Participate in 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and
- 1y agoAMPYANIKATROCSV+10Sidoti Events, LLC's Virtual December Small-Cap ConferenceACCESS NewswireNEW YORK, NY / ACCESSWIRE / December 3, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place
- 1y agoANIKAnika To Participate in December 2024 Investor ConferencesGlobeNewswireBEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will participate
- 2y agoANIKAnika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoANIKAnika Reports Third Quarter 2024 Financial ResultsGlobeNewswireUpdating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds Strategy to
- 2y agoANIKAnika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus MedicalGlobeNewswireBEDFORD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced the divestiture of its
- 2y agoANIKAnika Announces Third Quarter 2024 Results Conference Call DateGlobeNewswireBEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024
- 2y agoANIKAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika granted
- 2y agoANIKAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024, Anika granted